The association between end-stage diabetic nephropathy and methylenetetrahydrofolate reductase genotype with macroangiopathy in type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 111, Issue 3, 2003, Pages 132-138

  Hasegawa, Goji ^a   Obayashi, H ^b   Kamiuchi, K ^a   Nakai, M ^c   Kanatsuna, T ^c   Yamaguchi, M ^d   Tanaka, T ^d   Shigeta, H ^d   Fujii, M ^e   Yoshikawa, T ^a   Nakamura, N ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Kyoto Microbiological Institute   (Japan)

^c Nishijin Hospital   (Japan)

^d KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^e Kobe Central Hospital   (Japan)

Author keywords

Atherosclerosis; Methylenetetrahydrofolate reductase; Polymorphism; Renal failure

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); GENOMIC DNA; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED;

EID: 0037643521     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39785     Document Type: Article

References (36)

1. Alberti KGMM, Zimmet PZ (for the WHO consultation). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-553
2. Anderson JL, King GJ, Thomson MJ, Todd M, Bair TL, Muhlestein JB, Carlquist JF. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 1997; 30: 1206-1211
3. Arai K, Yamasaki Y, Kajimoto Y, Watada H, Umayahara Y, Kodama M, Sakamoto K, Hori M. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM. Diabetes 1997; 46: 2102-2104
4. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52
5. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6: 121-125
6. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554-2558
7. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59-62
8. Bostom AG, Gohh RY, Bausserman L, Hakas D, Jacques PF, Selhub J. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. J Am Soc Nephrol 1999; 10: 164-166
9. Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol 1999; 19: 2922-2927
10. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS. The hemodialysis (HEMO) study. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362
11. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A, Gonzalez-Sastre F, Blanco-Vaca F. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease. Diabetologia 1998; 41: 684-693
12. Dierkes J, Domrose U, Ambrosch A, Schneede J, Guttormsen AB, Neumann KH, Luley C. Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism 1999; 48: 631-635
13. Franken DG, Boers GHJ, Blom HJ, Trijbels JM, Kloppenborg PWC. Effect of various regimens of vitamin B6 and folic acid on mild hyperhomocysteinemia in vascular patients. J Inherited Metab Dis 1994; 17: 159-162
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthewes RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozan R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113
15. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Muller E, Schmid R, Horl WH, Sunder-Plassmann G. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-523
16. Gardemann A, Weidemann H, Philipp M, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The TT genotype of the methylenetetrahydrofolate reductase C677 Tgene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J 1999; 20: 584-592
17. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the third national health and nutrition examination survey. Am Heart J 2000; 139: 446-453
18. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales LA, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-1781
19. Harker LA, Ros R, Slichter S, Scott RC. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741
20. Hultberg B, Anderson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40. 230-235
21. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeld JH, Rosenberg IH, Selhub J, Rozen R. Relationship between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9
22. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Donker AJM, Stehouwer CDA. Serum homocysteine levels are associated with the development of (micro)albuminuria: The Hoorn study. Arterioscler Thromb Vasc Biol 2001; 21: 74-81
23. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidative stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens 2000; 9: 477-487
24. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-1695
25. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-2416
26. Mazza A, Motti C, Nulli A, Marra G, Gnaso A, Pastore A, Federici G, Cortese C. Lack of association between carotid intima-media thickness and methylenetetrahydrofolate reductase gene polymorphism or serum homocysteine in non-insulin-dependent diabetes mellitus. Metabolism 2000; 49: 718-723
27. Morita H, Taguchi JI, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032-2036
28. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-141
29. Selhub J,Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698
30. Stanford JL, Molina H, Phillips J, Kohlman-Trigoboff D, Moore J, Smith BM. Oral folate reduces plasma homocyst(e)ine levels in hemodialysis patients with cardiovascular disease. Cardiovasc Surg 2000; 8: 567-571
31. Sunder-Plassmann G, Födinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, Enzenberger B,Janata O, Winkelmayer WC, Paul G, Auinger M, Barnas U, Horl WH. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000; 11: 1106-1116
32. Vychytil A, Födinger M, Wölfl G, Enzenberger B, Auinger M, Prischl F, Buxbaum M, Wiesholzer M, Mannhalter C, Höri WH, Sunder-Plassmann G. Major determinants of hyperhomocycteinemia in peritoneal dialysis patients. Kidney Int 1998; 53: 1775-1782
33. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980; 18: 113-121
34. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172
35. Wilcken DEL, Wang XL, Adachi T, Hara H, Duarte N, Green K, Wilcken B. Relationship between homocysteine and superoxide dismutase in homocystinuria. Possible relevance to cardiovascular risk. Arterioscler Thromb Vasc Biol 2000; 20: 1199-1202
36. Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 55: 1028-1035